Agenus Inc. (AGEN)

13,47 +0,21 (+1,58%) In data: 11:44AM EDT. Mercato aperto.

Agenus Inc.

3 Forbes Road
Lexington, MA 02421-7305
United States
781 674 4400
https://www.agenusbio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 389

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Garo H. Armen Ph.D.	Founder, Executive Chairman & CEO	1,34M	N/D	1953
Ms. Christine M. Klaskin	VP of Finance, Principal Financial Officer & Principal Accounting Officer	407,44k	N/D	1966
Dr. Steven J. O'Day M.D., Ph.D.	Chief Medical Officer	970,98k	N/D	1961
Craig Winter	Chief Information Officer	N/D	N/D	N/D
Mr. Zack Armen	Head of Investor Relations	N/D	N/D	N/D
Ms. Tracy Mazza Clemente	Chief People Officer	N/D	N/D	N/D
Mr. Alfred Dadson	Chief Manufacturing Officer	N/D	N/D	N/D
Mr. Eric Humes	Chief Quality Officer	N/D	N/D	N/D
Dr. Todd Jude Yancey M.D.	Member of Advisory Board & Chief Strategic Advisor	N/D	N/D	N/D
Dr. Robin G. Taylor M.B.A., Ph.D.	Chief Commercial Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Agenus Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.